Keskin Havva, Cadirci Kenan, Demirkazik Ahmet, Akbulut Hakan, Yalcin Bulent
Department of Internal Medicine, Istanbul Medeniyet University Training and Research Hospital, Istanbul, Turkey.
Department of Internal Medicine, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.
Biomark Cancer. 2019 Jun 10;11:1179299X19854447. doi: 10.1177/1179299X19854447. eCollection 2019.
Several problems such as myalgia, arthralgia, fever, dyspnea, generalized edema, and pleural effusion can occur in cancer patients following the chemotherapy, especially at the first cycle of the first chemotherapy treatment. Although it is assumed that some cytokines are associated with the development of these symptoms and signs, their pathophysiology has not been discovered completely yet. They are usually mild, but they may rarely progress to the severe stage of "Systemic Capillary Leak Syndrome" with a high mortality rate. The objective of this study was to investigate the association between the serum levels of interleukin-2 (IL-2), interleukin-11 (IL-11), tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), and these symptoms and signs. A total of 44 cancer patients who had neither heart, lung, liver, renal, or thyroid disease were recruited into this study. Their symptoms and signs were examined and questioned before the first cycle of the first chemotherapy treatment and the 24 h after this chemotherapy. All participant's serum samples were taken, and the VEGF, TNF, IL-2, and IL-11 levels were studied. There was no association between the chemotherapeutic drugs, and the symptoms and signs such as edema, dyspnea, coughing, and flu-like symptoms. There was a significant decrease in IL-11 levels in the other treatment group compared with the group receiving paclitaxel, docetaxel, gemcitabine, and vinorelbine in the first day following chemotherapy ( = .006). However, no relation was observed between the symptoms and signs, the response to the chemotherapy, and the serum levels of VEGF, TNF, IL-2, and IL-11. These symptoms and life-threatening syndrome have been a current topic between the clinicians. Although some drugs and mediators are accused, its pathophysiology has not been discovered completely yet. In this study, we could not detect any association between the symptoms, signs, and the cytokine levels following the chemotherapy.
癌症患者化疗后可能会出现多种问题，如肌痛、关节痛、发热、呼吸困难、全身性水肿和胸腔积液等，尤其是在首次化疗的第一个周期。尽管推测某些细胞因子与这些症状和体征的发生有关，但其病理生理学尚未完全明确。这些症状通常较轻，但极少数情况下可能进展为死亡率很高的“系统性毛细血管渗漏综合征”的严重阶段。本研究的目的是探讨血清白细胞介素 -2（IL -2）、白细胞介素 -11（IL -11）、肿瘤坏死因子α（TNF -α）、血管内皮生长因子（VEGF）水平与这些症状和体征之间的关联。本研究共纳入44例无心脏、肺、肝、肾或甲状腺疾病的癌症患者。在首次化疗的第一个周期前及化疗后24小时对他们的症状和体征进行检查并询问。采集所有参与者的血清样本，检测VEGF、TNF、IL -2和IL -11水平。化疗药物与水肿、呼吸困难、咳嗽和流感样症状等症状和体征之间无关联。与接受紫杉醇、多西他赛、吉西他滨和长春瑞滨治疗的组相比，另一治疗组在化疗后第一天IL -11水平显著降低（ = 0.006）。然而，未观察到症状和体征、化疗反应与VEGF、TNF、IL -2和IL -11血清水平之间的关系。这些症状和危及生命的综合征一直是临床医生关注的热点话题。尽管有一些药物和介质被怀疑与此有关，但其病理生理学尚未完全明确。在本研究中，我们未检测到化疗后症状、体征与细胞因子水平之间存在任何关联。
